Literature DB >> 22154082

Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions.

Baris Ozturk1, Ediz Tutuncu, Ferit Kuscu, Yunus Gurbuz, Irfan Sencan, Hakan Tuzun.   

Abstract

BACKGROUND: Crimean-Congo hemorrhagic fever (CCHF) is one of the viral hemorrhagic fevers caused by tick bites. Common symptoms of the infection are fatigue, high fever, headache, and myalgia. In some patients hemorrhage may accompany these symptoms and is a sign of a poor prognosis. Typical laboratory changes are thrombocytopenia, leukopenia, elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), and lactate dehydrogenase (LDH), and prolongation of prothrombin time (PT) and activated partial thromboplastin time (aPTT). Mortality rates vary between 3% and 30%. The aim of this study was to determine the factors affecting the prognosis of CCHF.
METHODS: A total of 70 patients with a diagnosis of CCHF who were followed at our clinic between 2005 and 2008 were included in this study. As well as patient clinical history, biochemical parameters tested during the first 5 days and the prognosis were evaluated. Findings were compared between patients who died and those who recovered. Non-parametric statistical tests were used for the statistical analysis.
RESULTS: When the laboratory parameters of patients who died and recovered were compared, PT, aPTT, international normalized ratio (INR), AST, LDH, fibrinogen, C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), D-dimer, IgM, IgG, C3 and C4 levels, and platelet count were found to be positively related with fatality. On the other hand, there was no significant difference between groups regarding ALT, CPK, prealbumin, ceruloplasmin, protein C, protein S, and antithrombin III levels, and white blood cell counts.
CONCLUSIONS: It is essential to determine the possibility of a fatal prognosis in CCHF patients using clinical history and biochemical parameters so that the necessary precautions can be taken.
Copyright © 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154082     DOI: 10.1016/j.ijid.2011.06.005

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  15 in total

1.  A retrospective controlled study of thiol disulfide homeostasis as a novel marker in Crimean Congo hemorrhagic fever.

Authors:  Zeliha Kocak Tufan; Imran Hasanoglu; Servet Kolgelier; Murat Alisik; Merve Ergin; Gul Ruhsar Yilmaz; Mehmet A Tasyaran; Ozcan Erel; Rahmet Guner
Journal:  Redox Rep       Date:  2016-05-09       Impact factor: 4.412

Review 2.  Immunobiology of Crimean-Congo hemorrhagic fever.

Authors:  Sergio E Rodriguez; David W Hawman; Teresa E Sorvillo; T Justin O'Neal; Brian H Bird; Luis L Rodriguez; Éric Bergeron; Stuart T Nichol; Joel M Montgomery; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2022-01-11       Impact factor: 10.103

Review 3.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

4.  Crimean-Congo haemorrhagic fever presenting with acute compartment syndrome of the extremities (think beyond normal infections).

Authors:  Ishma Aijazi; Fadhil Mustafa Abdulla Al Shama; Yaseen Shandala; Rupa Murthy Varghese
Journal:  BMJ Case Rep       Date:  2020-02-06

5.  Association Between Severity Grading Score And Acute Phase Reactants In Patients With Crimean Congo Hemorrhagic Fever.

Authors:  Ilkay Bozkurt; Saban Esen
Journal:  Pathog Glob Health       Date:  2021-01-23       Impact factor: 2.894

6.  Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009.

Authors:  Nicholas G Conger; Kristopher M Paolino; Erik C Osborn; Janice M Rusnak; Stephan Günther; Jane Pool; Pierre E Rollin; Patrick F Allan; Jonas Schmidt-Chanasit; Toni Rieger; Mark G Kortepeter
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

7.  Apoptosis-Related Gene Expression in an Adult Cohort with Crimean-Congo Hemorrhagic Fever.

Authors:  Nil Guler; Cafer Eroglu; Hava Yilmaz; Adil Karadag; Hasan Alacam; Mustafa Sunbul; Tom E Fletcher; Hakan Leblebicioglu
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

8.  Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients.

Authors:  Yunus Gurbuz; Baris Ozturk; Emin Ediz Tutuncu; Irfan Sencan; Gonul Cicek Senturk; Fatma Aybala Altay
Journal:  Jundishapur J Microbiol       Date:  2015-10-20       Impact factor: 0.747

9.  A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.

Authors:  Karen R Buttigieg; Stuart D Dowall; Stephen Findlay-Wilson; Aleksandra Miloszewska; Emma Rayner; Roger Hewson; Miles W Carroll
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

10.  Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates.

Authors:  Ronald B Reisler; Chenggang Yu; Michael J Donofrio; Travis K Warren; Jay B Wells; Kelly S Stuthman; Nicole L Garza; Sean A Vantongeren; Ginger C Donnelly; Christopher D Kane; Mark G Kortepeter; Sina Bavari; Anthony P Cardile
Journal:  Emerg Infect Dis       Date:  2017-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.